Skip to content Skip to left sidebar Skip to footer

Notices

Vaccine Updates: Moderna Life Span Approval, Training and Resources & July 4th Deliveries

Vaccine Updates: Moderna Life Span Approval, Training and Resources & July 4th Deliveries

ACIP voted unanimously to recommend the Moderna 6-17 COVID vaccine, allowing for Moderna products to be used to vaccinate the full life span. Please see wallchart below for product breakdown: 
  • Moderna 6-11 Years: A two-dose Moderna COVID-19 vaccines series (50ug) is recommended for children ages 6-11 years, under the EUA issued by FDA.
    • Ordering for this product, Dark Blue Cap/Purple Border, will open next week in Philavax on the 29th. Monday.com ordering will open the following week.
  • Moderna 12-17 Years: A two-dose Moderna COVID-19 vaccines series (100ug) is recommended for children ages 12-17 years, under the EUA issued by FDA.

Training and Resources

MODERNA VIAL PRESENTATIONS, DHCP LETTER, ETC.  
WEBINAR INVITE: MODERNA PEDIATRIC COVID-19 VACCINE INDICATION (REGISTER)Please join us for one of our upcoming webinars detailing the pediatric and adolescent indications for the Moderna COVID-19 vaccine. Webinars will be held:
  • Tuesday, June 28 at 3 pm ET (2 pm CT / 12 pm PT)
  • Thursday, July 7 at 12 pm ET (11 am CT / 9 am PT)
  • Tuesday, July 12 at 2 pm ET (1 pm CT / 11 am PT)
  • Tuesday, July 19 at 12 pm ET (11 am CT / 9 am PT)
If you’d like to attend more than one webinar, please register for each date separately. The same topics will be covered in all webinars.Pfizer Medical Updates & Immunization Site Training for all Healthcare Providers led by Pfizer Vaccines US Medical Affairs: 
  • Trainings now include presentations on COVID-19 vaccines with a MAROON Cap for individuals 6 months through 4 years of age.
  • For details, see dates and links for upcoming training sessions.
  • Daily trainings (Monday through Friday) will begin Monday, June 20, 2022, and continue at least through July 8, 2022 (with no training on July 4th).
Videos:Intramuscular (IM) Injection: Supplies (Children Birth through 18 Years of Age): This training addresses how to select the equipment needed to prepare an intramuscular (IM) injection for children from birth through 18 years of age. A supply of needles of the appropriate lengths should be available. Aseptic technique must be used to protect supplies from microbial contamination. Safe injection practices minimize risk of injuries, infections, and non-infectious adverse events for both patients and providers. Health care providers are always advised to observe patients for 15 minutes after vaccination.Intramuscular (IM) Injection: Sites: This training helps providers identify intramuscular (IM) injection sites. A needle is used to inject the vaccine into the muscle. The appropriate site for an intramuscular injection for those under 2 years of age is the vastus lateralis muscle. The deltoid muscle over the triceps area of the upper arm is preferred for persons 3 years of age and older. Safe injection practices minimize risk of injuries, infections, and non-infectious adverse events for both patients and providers. Health care providers are always advised to observe patients for 15 minutes after vaccination.

Fourth of July Deliveries

Moderna and J&J/Janssen Vaccines
  • No vaccine deliveries will occur Saturday July 2 through Tuesday, July 5, 2022.
Pfizer-BioNTech Vaccines
  • No vaccine deliveries will occur on Saturday, July 2 through Monday, July 4, 2022.

Key Messages for Younger Pediatric COVID-19 Vaccination

Key Messages for Younger Pediatric COVID-19 Vaccination

On Saturday, June 18th, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation to expand COVID-19 vaccination to children younger than 5 years of age. This decision now universally recommends COVID-19 vaccination for everyone 6 months and older, paving the way for about 20 million children in this age group to get vaccinated and allowing providers to begin vaccinating with either the Moderna or the Pfizer-BioNTech vaccine as soon as possible.


KEY DATES

  • If you placed an order in Philavax before 6/8/22 at 5pm, your order will be arriving between the 21st and 24th.
  • If you placed an order in Philavax between 6/8/22 – 6/22/22 at 5pm, your order will most likely be arriving the week of the 27th (exact delivery TBD).
  • If you placed an order via Monday.com before 6/22/22 at 5pm, your order will be arriving 6/28/22.
  • ACIP will be meeting to discuss recommendations for the recently authorized Moderna COVID-19 Vaccine for ages 6-17 years on June 23rd.


KEY MESSAGES   

CDC recommends that everyone 6 months and older get vaccinated against COVID-19. 
  • Parents make decisions every day to protect their children, and now COVID-19 vaccines are available to protect all children 6 months and older.
  • Both the Moderna and Pfizer-BioNTech COVID0-19 vaccines have been approved for children ages 6 months through 5 years.
  • The Moderna vaccine for children ages 6 months through 5 years will be a two-dose primary series.
  • The Pfizer-BioNTech vaccine for children ages 6 months through 4 years will be a three-dose primary series.
Vaccinating everyone, including children 6 months and older, provides the best defense against serious outcomes related to COVID-19. Both COVID-19 vaccines for children are safe and protect against severe illness from COVID-19.
  • Thousands of children were part of robust clinical trials to evaluate the safety of the COVID-19 vaccines and how well they worked.
  • Parents and caregivers are encouraged to register their children for v-safe to share how their child is feeling after vaccination. V-safe uses confidential text messaging and web surveys to provide personalized health check-ins following COVID-19 vaccination.
  • To help enroll more children in v-safe, providers are encouraged to give families information on v-safe (and why it is important and beneficial) at the time of vaccination.
  • Children and teens can get a COVID-19 vaccine and other routinely recommended vaccines, including a flu vaccine, at the same visit.
Parents and caregivers should get their child vaccinated with the COVID-19 vaccine that is available to them.  
  • To find COVID-19 vaccines for children, parents and caregivers can talk to a doctor, nurse, pharmacist, visit vaccines.gov.
    • VaccineFinder should be updated to search for under five vaccines on WED/THUR.
After getting a COVID-19 vaccine, children may have some side effects similar to those seen with other routine childhood vaccines.
  • Reported side effects tend to be mild and temporary. Some children have no side effects.​
  • Serious health events, like myocarditis, after COVID-19 vaccination in children are rare. When they are reported, side effects occur most frequently within a few days after vaccination.
The benefits of COVID-19 vaccination outweigh the known and potential risks.  

RESOURCES

Information for jurisdictions, clinicians, vaccine providers, and community partners to plan and implement vaccination for children who are eligible: 
Information for parents and caregivers: 
Links to EUAs and Dear HCP Letters:

Upcoming Under 5 Vaccine Info Sessions

Upcoming Under 5 Vaccine Info Sessions

Pfizer and Moderna under 5 vaccines are tentatively scheduled for delivery between the 21st to 24th. As these dates are quickly approaching, PDPH will be offering provider information sessions next week (dates below). These sessions will cover what we currently know about the under 5 vaccines. It will also provide resources and links where providers can go to access additional information, updates, and tools. Pfizer is also offering info sessions next week (dates below as well). Moderna will begin offering info sessions once their vaccine is approved.

Date Training Type Link
Tuesday, June 14, 2022Time: 12pm (Noon) PDPH – Under Five Vaccines Overview ZOOM Meeting LinkOr join via phone:

      • +1 301 715 8592 US

    Meeting ID: 878 2006 3335

    Passcode: 075328

 

Tuesday, June 14, 2022Time: 3pm Pfizer – Medical Updates & Immunization Site Training for All Healthcare Providers Invite Link
Wednesday, June 15, 2022Time: 9am PDPH – Under Five Vaccines Overview ZOOM Meeting LinkOr join via phone:

      • +1 301 715 8592 US

    Meeting ID: 885 1619 9101

    Passcode: 301147

 

Wednesday, June 15, 2022Time: 12pm (Noon) Pfizer – Medical Updates & Immunization Site Training for All Healthcare Providers Invite Link
Thursday, June 16, 2022Time: 9am PDPH – Under Five Vaccines Overview ZOOM Meeting LinkOr join via phone:

      • +1 301 715 8592 US

    Meeting ID: 849 7433 4043

    Passcode: 913339

 

Thursday, June 16, 2022Time: 12pm (Noon) Pfizer – Medical Updates & Immunization Site Training for All Healthcare Providers Invite Link

 

PREP Act: Pharmacists Cannot Vaccinate Children Under Age 3

PREP Act: Pharmacists Cannot Vaccinate Children Under Age 3

In preparation for the rollout of under 5 vaccines, we wanted to reminder COVID-19 vaccine providers about the PREP Act, its coverage, and limitations. While many pharmacies are planning for a COVID-19 vaccination program for children under 5 years and have also been critical in the distribution of COVID-19 vaccines for other age groups, their ability to vaccinate these children (under 5) may be limited for various reasons (i.e., PREP Act Declaration authorizations).

The Public Readiness and Emergency Preparedness (PREP) Act and the PREP Act Declaration issued by the Secretary of the U.S. Department of Health and Human Services (HHS) authorize and provide liability protections to licensed providers and others identified in the declaration to administer COVID-19 vaccines authorized or approved by FDA, including COVID-19 vaccines authorized for administration to children. Subject to certain requirements, the recent PREP Act Declaration Third Amendment and HHS guidance authorize licensed pharmacists to order and administer ACIP-recommended vaccines to children ages 3 through 18. Due to this specification, children under the age of 3 are unable to be vaccinated by pharmacists/at pharmacies. It is recommended that pharmacists direct parents of children in this age group to vaccines.gov to find a provider who can offer them vaccination services.

For providers with additional questions regarding the PREP act, please see the following PREP Act guidance.

Pre-Ordering for Under 5 Vaccines Now Open in Philavax

Pre-Ordering for Under 5 Vaccines Now Open in Philavax

Pfizer-BioNTech and Moderna are conducting clinical trials and data collection for COVID-19 vaccines for children ages 6 months through 4 years and 6 months through 5 years, respectively. Both companies have submitted data for review to the FDA. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is tentatively scheduled to meet on June 15, 2022, to discuss both the Pfizer-BioNTech vaccine for children aged 6m–4 years and the Moderna vaccine for children aged 6m–5 years. The CDC’s Advisory Committee on Immunization Practices (ACIP) is anticipated to meet within several days of VRBPAC, to make official recommendations.

In anticipation of the vaccine rollout, pre-ordering for both of these formulations (Moderna and Pfizer) is now open in Philavax. Between now and Wednesday, the 8th, at 5pm, COVID-19 vaccine providers can place a pre-order for the under 5 vaccines. Submission of both a temperature log and a reconciliation is also required to process provider orders. While both formulations (Moderna and Pfizer) will be available for ordering in the system, providers are strongly encouraged to order and stick with one under 5 vaccine product/manufacturer in order to prevent administration and handling errors.

Shipment of Pfizer-BioNTech COVID-19 vaccine for ages 6m–4 years and/or Moderna COVID-19 vaccine for ages 6m–5 years is planned to begin once FDA issues the EUA(s), tentatively arriving between the 23rd-29th. However, vaccine administration can only begin following the CDC/ACIP recommendation(s).

Here’s what we know about both vaccines so far (which could change pending FDA review):

VFC/VFAAR Re-Enrollment Begins Today!

VFC/VFAAR Re-Enrollment Begins Today!

The Philadelphia Vaccines for Children (VFC)/ Vaccines for Adults at Risk (VFAAR) annual re-enrollment period is now open! Sites enrolled in VFC or VFAAR must submit a re-enrollment form by June 30 in order to continue to participate in these programs.

For a smoother re-enrollment, complete these steps before beginning the enrollment form:

1. Update Clinic Tools
Review the information indicated for your site in the Clinic Information module. Use these job aids to guide you though making the necessary updates:

2. Make sure you have the correct level of access to PhilaVax.
The vaccine coordinator and medical director must log into the PhilaVax IIS to access, complete, and sign the electronic re-enrollment form. If you have not completed the 2022 User Confidentiality Agreement to renew your account or do not have a PhilaVax user account, use the link below to complete it now.

PhilaVax User Confidentiality Agreement
If you have trouble accessing the above link or you have a PhilaVax account and need to update your password, you can email PhilaVax@phila.gov for assistance.

Once these steps are complete, use these job aids to guide you through the enrollment form step by step:

We’re here to help! If you’re having trouble, email DPHProviderHelp@phila.gov to connect with our team.

CDC Expands Eligibility for COVID-19 Booster Shots

CDC Expands Eligibility for COVID-19 Booster Shots

Following yesterday’s meeting of the Advisory Committee on Immunization Practices, CDC is expanding eligibility of COVID-19 vaccine booster doses to everyone 5 years of age and older. CDC now recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series.

Since the pandemic began, more than 4.8 million children ages 5 through 11 have been diagnosed with COVID-19, 15,000 have been hospitalized and, tragically, over 180 have died. As cases increase across the country, a booster dose will safely help restore and enhance protection against severe disease.

VFC/VFAAR Re-enrollment is Right Around the Corner!

VFC/VFAAR Re-enrollment is Right Around the Corner!

The Philadelphia Vaccines for Children (VFC)/ Vaccines for Adults at Risk (VFAAR) annual re-enrollment period will take place from June 1 to 30, 2022. For the third year, the enrollment will be done electronically through PhilaVax.

To get your site ready for re-enrollment, complete these steps now.

1. Update Clinic Tools
Review the information indicated for your site in the Clinic Information module. Use these job aids to guide you though making the necessary updates:

2. Make sure you have the correct level of access to PhilaVax.
The vaccine coordinator and medical director must log into the PhilaVax IIS to access, complete, and sign the electronic re-enrollment form. If you have not completed the 2022 User Confidentiality Agreement to renew your account or do not have a PhilaVax user account, use the link below to complete it now.

PhilaVax User Confidentiality Agreement
If you have trouble accessing the above link or you have a PhilaVax account and need to update your password, you can email PhilaVax@phila.gov for assistance.

Additional information and instructions will be communicated closer to the start of the re-enrollment period.
Re-enrollment is a requirement for the VFC/VFAAR programs. Failure to complete the re-enrollment form will result in un-enrollment.

Questions? Email our team at DPHProviderHelp@phila.gov.

New Vaccine Products Available through VFC

New Vaccine Products Available through VFC

10 dose boxes of pre-filled syringes of Quadracel (DTaP-IPV, NDC# 49281-0564-15, Sanofi) and of Recombivax HB (Hep B, NDC# 00006-4093-02, Merck) are now available to order through the VFC program.

If you would like to order either of these presentations for your site, please email our team at DPHProviderHelp@phila.gov or add a comment to your next order so that we can update your site’s permissions.

COVID Weekly Reporting Beginning May 1

Weekly Reporting Beginning May 1

UPDATE: As of May 1, 2022, providers are only required to report COVID-19 vaccine supply levels at least weekly by close of business on Fridays. Daily reporting of inventory to VaccineFinder is no longer required. All other requirements regarding data reporting, to the IIS for example, remain unchanged.

We appreciate your efforts to update data in VaccineFinder. If your site does not have access to VaccineFiner or needs to change the primary or backup contact for VaccineFinder, please reach out to covidproviders@phila.gov. Please note that only two individuals can receive registration links for VaccineFinder. In some instances, sites may only be able to have one individual reporting to VaccineFinder depending on how the account was initially setup.